81 results about "Alzheimer dementia" patented technology

Methods and compositions for treating or preventing, the occurrence of senile dementia of the Alzheimer's type, mild cognitive impairment, or other conditions arising from reduced neuronal metabolism and leading to lessened cognitive function are described. In a preferred embodiment the administration of triglycerides or fatty acids with chain lengths between 5 and 12, to said patient at a level to produce an improvement in cognitive ability, and a therapeutic agent selected from the group consisting of anti-Alzheimer's agents, anti-diabetic agents, agents capable of increasing utilization of lipids, anti-atherosclerotic agents, anti-hypertensive agents, anti-inflammatory agents, anti-obesity agents, and combinations thereof. Preferred therapeutic agents include donepezil, rivastigmine, galantamine, and memantine.

Methods and composition for treating or preventing, the occurrence of senile dementia of the Alzheimer's type, or other conditions arising from reduced neuronal metabolism and leading to lessened cognitive function are described. In a preferred embodiment the administration of novel esterified saccharide compounds to said patient at a level to produce an improvement in cognitive ability.

Methods and compositions for treating or preventing, the occurrence of senile dementia of the Alzheimer's type, or other conditions arising from reduced neuronal metabolism and leading to lessened cognitive function are described. In a preferred embodiment the administration of triglycerides or fatty acids with chain lengths between 5 and 12, to said patient at a level to produce an improvement in cognitive ability.

The invention relates to a method for processing rehmannia, which is characterized in that fresh rehmannia is freeze-dried; and with the adoption of the method for processing rehmannia disclosed by the invention, more active ingredients of rehmannia can be reserved. The medicine is prepared from fresh rehmannia or freeze-dried rehmannia and has remarkable treating effect on cancerous fever, habitual constipation, alopecia and Alzheimer disease.

The invention discloses a traditional Chinese medicine for preventing and treating Alzheimer disease and a preparation method thereof. The traditional Chinese medicine is prepared from the following raw materials in parts by weight: 12-16 parts of prepared fleece flower root, 8-12 parts of ginseng, 9-13 parts of rhizoma acori graminei, 5-9 parts of coptis and 6-10 parts of chuanxiong rhizome. The traditional Chinese medicine can be prepared into granules, capsules, soft capsules, dissolved medicines, dripping pills and soft extracts, has the advantages of simple manufacturing process and low cost, is completely prepared from natural plants, does not contain hormones, has no addition of pigments and other chemical synthetics, and does not have toxic side effects on human bodies after being continuously used. The traditional Chinese medicine contains various effective components such as flavones, saponins, phenolic acids, alkaloids, polysaccharides and the like capable of being easily absorbed by human bodies, can be effectively used for nourishing the kidney and invigorating the brain, replenishing qi and dissolving turbidity and promoting blood circulation and eliminating toxicity, and is suitable for treating deficiency of the kidney, mild cognitive impairment caused by obstruction of the orifices by blood stasis, Alzheimer disease and the like.

The invention relates to a preparation method of terpenoid and lignan substances in eucommia ulmoides bark or eucommia ulmoides leaves and an application of the terpenoid and lignan substances in preparation of senile dementia and AD (Alzheimer disease) treatment drugs or healthcare food. The prepared terpenoid substance in the eucommia ulmoides bark or the eucommia ulmoides leaves is one or more of 1-deoxy-delta4,5-eucommiol, 2,3-dyhydroxyl-delta4,5-eucommiol, 5-hydroxyl-3,4-dihydroxymethyl-2-hydroxyethyl-cyclohex- 1-enone-2'-O-beta-D-glucopyranoside), (6R, 7E, 9R)-megastigma-4,7-dien-3-one-9-O-[beta-D-xylopyranos-yl-(1'-6')-beta-D-glucopyranoside, (6S, 7E, 9R)-megastigma-4,7-dien-3-one-9-O-[beta-D-xylopyranos-yl-(1'-6')-beta-D-glucopyranoside] and the like. The prepared lignan substance in the eucommia ulmoides bark or the eucommia ulmoides leaves is one or more of pinoresinol-4,4'-O-beta-D-bis(glucopyranoside), 8-hydroxyl-pinoresinol-4'-O-beta-D-glucopyranoside, lariciresinol-4,4'-O-beta-D- bis(glucopyranoside) and the like. The terpenoid and lignan substances have common or similar structural units such as eucommiol, megastigmane sesquiterpene, bisepoxylignans, single-epoxy lignans and the like, thereby having the similar treatment effect in a human body.

An alkyl ether derivative represented by the formula: wherein R1, R2, R3, R4, m and n are as defined in the specification, or salts thereof exhibits synergistically improved anti-hypoxic activity when combined with a compound having an acetylcholine esterase inhibitory activity. Therefore, the combination according to the present invention is useful as a method for improving cerebral function. Further, a pharmaceutical composition containing the compound relating to the combination according to the present invention is useful for treatment and prevention of dysfunction of cerebral acetylcholine neurons in the sequelae of cerebrovascular dementia, senile dementia, Alzheimer's disease and ischemic cerebral lesion and in the cerebral apoplexy or the memory impairment caused by selective neuronal death.

The invention relates to a drug, in particular to a drug composition for improving dysmnesia alzheimer disease and a preparation method thereof. The drug composition of the invention is made of the following raw medicines according to the parts by weight of 90 grams of gymnadenia conopsea, 90 grams of radix polygoni multiflori preparata, 90 grams of acanthopanax, 90 grams of sealwort, 90 grams of milk veteh, 60 grams of angelica, 60 grams of medlar, 60 grams of shizandra berry, 60 grams of dogwood, 60 grams of polygala, 60 grams of grassleaf sweelflag rhizome, and 60 grams of red paeonia. The drug composition of the invention is made of fully natural Tibetan pharmaceuticals with high quality and without pollution and traditional Chinese medicines which are mixed reasonably and does not have any side effect. The drug composition for improving dysmnesia alzheimer disease is widely applied to school students younger than eighteen years old and the middle and old-aged brainworkers elder than 45 years old to take as well as the symptoms of feeblemindedness, dysmnesia and alzheimer disease, etc.

The present invention concerns the methods and compositions for treating depression and other behavioral and / or emotional disorders of the central nervous system by administering an agonist of hedgehog signaling. Other disorders amenable to treatment by the subject method include attention deficit hyperactive disorders, non-Alzheimer dementia, and various symptoms of memory loss. The present invention also concerns the methods and compositions for enhancing memory and / or cognitive functions, both in a patient suffering from ailment affecting these functions, and in a subject with no diagnosed deficit in memory or cognitive function. The methods and compositions of the present invention stimulate neurogenesis and differentiation, and enhance synaptic transmission of neurons.

An alkyl ether derivative represented by the formula:wherein R1, R2, R3, R4, m and n are as defined in the specification, or salts thereof exhibits synergistically improved anti-hypoxic activity when combined with a compound having an acetylcholine esterase inhibitory activity. Therefore, the combination according to the present invention is useful as a method for improving cerebral function. Further, a pharmaceutical composition containing the compound relating to the combination according to the present invention is useful for treatment and prevention of dysfunction of cerebral acetylcholine neurons in the sequelae of cerebrovascular dementia, senile dementia, Alzheimer's disease and ischemic cerebral lesion and in the cerebral apoplexy or the memory impairment caused by selective neuronal death.

The present invention relates to compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and / or prevention of Aβ-related pathologies such as Down's syndrome, β-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI (“mild cognitive impairment”), Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.

A method of reducing the effects of Alzheimer's Dementia can include a step of administering amoxicillin and Vitamin B12 to a patient experiencing Alzheimer Dementia. Another step of the method can include administering indomethacin to the patient. The patient can also receive an administration of S-adenosyl-L-methionine and selinium. It has also been found to be beneficial to include a step of administering ibuprofen and / or aspirin to the patient.

The invention relates to a new preparation method of catalpol of general formula (I), wherein R1 is a monosaccharide; R3, R4, R5 and R8 are H; while R6 is OH and R7 is -OCH2OH. The invention also relates to the application of the compound and the drug combination thereof in the prevention and treatment of Alzheimer disease and Parkinson disease, which provides the new preparation method of the compound and the drug combination thereof for researching and developing new drugs against the Alzheimer disease and the Parkinson disease, being beneficial to further develop natural pharmaceutical resources.

The invention provides a preparation method of cerebroside compounds with a high purify. The preparation method comprises the following steps: smashing Termitomyces albuminosus, performing lixiviation in ethanol, suction filtration and concentration to obtain a crude sample of an ethanol extractum educt, distributing by a solvent, finally obtaining two pure compounds through performing positive and reverse phase silica gel chromatographic column separation and repeated high performance liquid chromatography purification on a normal butanol layer crude sample, and identifying the compounds as cerebroside compounds through spectral analysis. The compounds have new chemical structures, are respectively named as termitomycesphin G (n=16) and termitomycesphin H (n=18), and both have obvious quasi nerve growth factor activities confirmed by experiments. The preparation method is applied to preparation of medicaments for preventing neurodegenerative diseases, such as senile dementia and the like, and is in particular applied to the preparation of the medicaments for treating the neurodegenerative diseases, such as Alzheimer's disease and the like. The chemical structure is as follows.

Furanone derivatives and the pharmaceutically acceptable salts thereof have cytoprotective activity and protective activity for neuroinflammation, and neurodegenerative disorders; they are useful in the treatment of stroke, cerebral ischemia, myocardial infarction, myocardial ischemia, chronic heart failure, inflammation and other oxidative stress-related conditions, as well as Alzheimer's disease and senile dementia; they are also useful in the manufacture of pharmaceutical formulations for the treatment of such conditions.

The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain aryl-amido-aryl compounds of the following formula (for convenience, collectively referred to herein as “AAA compounds”), which, inter alia, are (selective) retinoic acid receptor α (RARα) agonists. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to (selectively) activate RARα, and in the treatment of diseases and conditions that are mediated by RARα, that are ameliorated by the activation of RARα, etc., including cognitive disorders, memory impairment, memory deficit, senile dementia, Alzheimer's disease, early stage Alzheimer's disease, intermediate stage Alzheimer's disease, late stage Alzheimer's disease, cognitive impairment, and mild cognitive impairment.

The present invention provides an agent for improving mental disorders due to cerebral dysfunction and an agent for inhibiting vascular hyperpermeability each containing a hepatocyte growth factor. The agent for improving mental disorders according to the present invention is useful in improving mental disorders, particularly decline in learning and memory function, due to cerebral dysfunction occurred in blood circulation disorders in the brain (for example, cerebral infarction, cerebral hemorrhage, lacunar stroke, Biswanger's disease, cerebral thrombosis, subarachnoid hemorrhage, cerebrovascular moyamoya disease, carotid cerebral arterial fibrous muscular plasia, cerebral arterial sclerosis, internal carotid artery occlusion, hypertensive encephalopathy, cerebral edema, etc.) and neurodegenerative disorders (for example, multiple sclerosis, Parkinson's disease, Parkinson'syndrome, Huntington's chorea, cerebrovascular dementia and Alzheimer dementia), epilepsy, head injury, etc. The agent for inhibiting vascular hyperpermeability according to the present invention is efficacious to blood hyperpermeability in the brain due to blood circulation disorders in the brain (for example, cerebral infarction, cerebral hemorrhage, lacunar stroke, Biswanger's disease, cerebral thrombosis, subarachnoid hemorrhage, cerebrovascular moyamoya disease, carotid cerebral arterial fibrous muscular plasia, cerebral arterial sclerosis, internal carotid artery occlusion, hypertensive encephalopathy, cerebral edema, etc.), blood leakage, edema, subcutaneous hemorrhage and bleeding tendency due to vascular hyperpermeability in various tissues (including internal organs).

The present invention relates to novel compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and / or prevention of Aβ-related pathologies such as Downs syndrome, β-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI (“mild cognitive impairment”), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with diseases such as Alzheimer disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.

The invention relates to the technical field of antibody drugs, in particular to a humanized anti-A[beta] monoclonal antibody and an application thereof. The humanized anti-A[beta] monoclonal antibodyprovided by the invention can inhibit A[beta] monomer polymerization and protect nerve cells from being infected with A[beta] toxicity, has a certain effect of improving cognitive learning and memoryability of Alzheimer dementia model mice, and can be used for treatment and diagnosis of diseases and symptoms related to amyloidosis, such as the Alzheimer disease.

A nutritive product used as both medicine and food for preventing and treating senile dementia and improving memory power is prepared from clausena lansium, gastrodia tuber and juglans regia L.. Its preparing process is also disclosed.

The invention discloses application of cobra neurotoxin monomer molecules in treatment of senile dementia. The senile dementia, also known as Alzheimer disease, is a senile disease with progressive memory disorder, obstacle of judgment and reasoning ability as well as dyskinesia as main clinical features. Evidence shows that strong focal inflammatory responses exist in the brains of the patients with the senile dementia, and activated microglia and astrocytes exist near senile plaques; and the activated microglia and astrocytes can express a plurality of inflammatory cytokines, including interleukin-1[beta] (IL-1[beta]), tumor necrosisfactor-alpha (TNF-alpha) and the like. Therefore, experts suggest that neurodegeneration may be caused by inappropriate activation of immune and inflammatoryreactions in the brain; and super-strong immune reactions can attack nerve tissue "in the wrong direction", thereby causing neuron damage and death. In order to solve the problems, the invention discloses a group of cobra neurotoxin monomer molecules which can inhibit increase of contents of related inflammatory factors, namely the IL-1[beta]) and the TNF-alpha, in the hippocampus of rats with the senile dementia, as well as significantly shorten escape latency of the rats with the senile dementia after treatment in Morris water maze experiment.

The invention belongs to the technical field of immunity, in particular relates to recombinant antigen polypeptide for preventing and treating senile dementia and a fusion gene encoding the recombinant antigen polypeptide. The recombinant antigen polypeptide contains at least one immunopotetiation sequence and at least one human beta-amyloid peptide sequence, wherein, the human beta-amyloid peptide sequence is provided with an amino acid sequence as shown in SEQ ID NO:1 or SEQ ID NO:2, the immunopotetiation sequence is selected from SEQ ID NO:3, SEQ ID NO:4, a recombinant form of the SEQ ID NO:3 and the SEQ ID NO:4 or an amino acid sequence which has at least 90% homology with the two. The recombinant antigen polypeptide removes carboxyl-terminal toxic fragment of full-length human Abeta, improves safety of the antigen peptide Abeta, and recombines the immunopotetiation sequence, and enhances the immunogenicity of the antigen peptide Abeta.

The invention relates to the technical field of medicine, in particular to a medicine for preventing and treating Alzheimer's disease (AD). Research indicates that a compound shown in a formula I caninhibit activity of acetylcholinesterase and butyrylcholinesterase and protect nerve cells, thereby indicating that the compound can be used for preparing food and / or medicines for treating and / or preventing the AD. The compound is derived from medicinal fungus inonotus obliquus, has small side effects through verification and shows no physiological toxicity after gavage in 10 times dose.

The invention discloses an in-situ hybridization detection kit which comprises a hybridization probe and a marker. The invention further discloses a method for carrying out in-situ hybridization detection on the mRNA (messenger Ribonucleic Acid), which is closely related to the pathological evolution of the prophase of the Alzheimer's disease (AD), of a gene CD2AP by using the kit, and the method comprises the following steps of: (1) enabling the RNA to be detected in a substrate to be in contact with the hybridization probe under the condition that a stable hybridization complex can be formed by the hybridization probe and a target sequence, thereby forming the hybridization complex; and (2) detecting the hybridization complex. According to the kit and the method, disclosed by the invention, the expression function of the gene CD2AP can be detected at an mRNA level, the prophase earlier than an early phase detected by the existing clinical biochemical detection indicators and imaging medicine is detected, and the real mRNA level screening of the prophase lesion of the AD can be realized, thus the aim of preventive diagnosis and treatment is achieved. Meanwhile, the method disclosed by the invention is simple and convenient and is low in cost, thereby facilitating the popularization and application to hospitals.

The invention provides a medicinal composition for treating the Alzheimer's disease and a preparation method and application of the medicinal composition. Specifically, the invention provides the medicinal composition which is prepared from the following traditional Chinese medicines: ginseng, poria cocos, rehmannia, dogwood, polygala tenuifolia, rhizoma acori graminei, jujube kernels and platycladi seeds. The invention further provides a preparation method and application of the medicinal composition. The medicinal composition is capable of remarkably inhibiting over phosphorylation of downstream tau protein and increasing the expression level of CaMKII, and has long-term effectiveness and security in treatment on senile dementia, particularly the Alzheimer's disease.

The present invention relates to novel compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and / or prevention of Aβ-related pathologies such as Down's syndrome, β-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI (“mild cognitive impairment”), Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.

The invention provides benzimidazole and a derivative thereof, a medicinal composition which contains the benzimidazole and derivative thereof as active components and is used for preventing and treating neurological and psychotic diseases, and application thereof in preparation of medicaments and functional foods for resisting senility, senile dementia and other neurological and psychotic diseases. The benzimidazole and derivative thereof provided by the invention can be prepared into pharmaceutical preparations of various forms, including oral administration, injection, lung inhalation and transdermal preparations, and specifically including injections, oral liquids, tablets, capsules, granules, aerosols, dry powder inhalers, sprays, plasters and the like.

The invention discloses an optical instrument for preventing and improving an Alzheimer disease. The optical instrument is characterized in that the optical instrument includes a light shielding cover body for covering eyes to form a space in front of the eyes and at least one a light source which is arranged in the cover body and flashes with a predetermined frequency. The invention also discloses a method for using the optical instrument for preventing and improving an Alzheimer disease. The method is characterized by comprising a step of covering the eyes with the light shielding cover body to form the space in front of the eyes and a step of using light to flash in a predetermined frequency and intensity in the light shielding cover body. According to the optical instrument and the method, through light sensing of the eyes, slow gamma waves of a brain are affected, and an effect of preventing and improving an Alzheimer disease is achieved.

The invention discloses a pill composition used for preventing and treating Alzheimer disease and a preparation method thereof, in particular a pill composition used for preventing and treating the Alzheimer disease, which is prepared from an active ingredient (-)-epigallocatechin gallate (EGCG) and pharmaceutically acceptable accessories, and a preparation method for the pill composition. The invention has the outstanding characteristic of providing the pill composition which is safe, effective, quality-controllable and convenient to use for patients suffering from the Alzheimer disease.